Dados B3 › KRSA3 × NATU3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | KRSA3 | NATU3 | year |
|---|---|---|---|
| ROE | -64.9% | -16.1% | 2025 |
| ROIC | 4.1%! | 11.1% | 2025 |
| ROA | -8.6% | -7.2% | 2025 |
| Gross margin | 18.9% | 66.6% | 2025 |
| EBIT margin | 9.3% | 6.5% | 2025 |
| Net margin | -17.7% | -8.2% | 2025 |
| Net debt/EBITDA | 7.94x | 1.57x | 2025 |
| Current ratio | 1.71x | 1.65x | 2025 |
| Revenue growth (1y) | 5.1% | 2.6% | 2025 |
| Revenue growth (5y CAGR) | 31.2% | 3.5% | 2025 |
| Piotroski F-Score | 4/9 | 1/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | KRSA3 | NATU3 | year |
|---|---|---|---|
| P/E | -3.83x | -8.57x | 2024 × 2025 |
| P/B | 0.83x | 1.18x | 2024 × 2025 |
| EV/EBITDA | 7.81x | 8.43x | 2024 × 2025 |
| FCF yield | -23.4% | -3.2% | 2024 × 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:12 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it